수술적 치료와 Posaconazole 사용으로 완치된 비안와뇌형 털곰팡이증
A Case of Rhino-Orbital-Cerebral Mucormycosis Successfully Treated by Surgical Treatment and Posaconazole
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Mucormycosis is a highly aggressive and fatal fungal infection. Due to its rapid progression, combination of early wide surgical debridement with administration of antifungal agent is extremely crucial. European Society for Clinical Microbiology and Infectious Diseases, and European Confedration of Medical Mycology recommended amphotericin B as the first-line of treatment and posaconazole as the salvage agent for mucormycosis. We report a case of rhino-orbital-cerebral mucormycosis successfully treated by changing antifungal agent from the first-line amphotericin B to the salvage agent posaconazole. A 57-years-old female with uncontrolled type 2 diabetes mellitus was presented with foot abscess and rhino-orbital-cerebral mucormycosis. The infection was intractable despite orbital orbital exenteration with surgical debridement and 2 months of antibiotics treatment including amphotericin B. Changing amphotericin B to posaconazole resulted in clinical improvement within the first week. Conclusively the newly administered antifungal agent, posaconazole is expected to be an effective salvage treatment option for mucormycosis after failure of initial treatment of amphotericin B with surgical management.
Abstract
Mucormycosis is a highly aggressive and fatal fungal infection. Due to its rapid progression, combination of early wide surgical debridement with administration of antifungal agent is extremely crucial. European Society for Clinical Microbiology and Infectious Diseases, and European Confedration of Medical Mycology recommended amphotericin B as the first-line of treatment and posaconazole as the salvage agent for mucormycosis. We report a case of rhino-orbital-cerebral mucormycosis successfully treated by changing antifungal agent from the first-line amphotericin B to the salvage agent posaconazole. A 57-years-old female with uncontrolled type 2 diabetes mellitus was presented with foot abscess and rhino-orbital-cerebral mucormycosis. The infection was intractable despite orbital orbital exenteration with surgical debridement and 2 months of antibiotics treatment including amphotericin B. Changing amphotericin B to posaconazole resulted in clinical improvement within the first week. Conclusively the newly administered antifungal agent, posaconazole is expected to be an effective salvage treatment option for mucormycosis after failure of initial treatment of amphotericin B with surgical management.
참고문헌 (20)
- Bitar D, "Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006", Emerg Infect Dis, 15, pp.1395~1401 (2009)
- Rees JR, "The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993:results of population-based laboratory active surveillance", Clin Infect Dis, 27, pp.1138~1147 (1998)
- Fanfair RN, "Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011", N Engl J Med, 367, pp.2214~2225 (2012)
- Roden MM, "Epidemiology and outcome of zygomycosis : a review of 929 reported cases", Clin Infect Dis, 41, pp.634~653 (2005)
- Langner S, "Posaconazole in the management of refractory invasive fungal infections", Ther Clin Risk Manag, 4, pp.747~758 (2008)
- Pinto ME, "Hyperglycemic hyperosmolar state and rhino-orbital mucormycosis", Diabetes Res Clin Pract, 91, pp.e37~e39 (2011)
- Artis WM, "A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis : transferrin and iron availability", Diabetes, 31, pp.1109~1114 (1982)
- Medoff G, "Pulmonary mucormycosis", N Engl J Med, 286, pp.86~87 (1972)
- Tedder M, "Pulmonary mucormycosis : results of medical and surgical therapy", Ann Thorac Surg, 57, pp.1044~1050 (1994)
- Cornely OA, "ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013", Clin Microbiol Infect, 20, pp.5~26 (2014)
- Gomes MZ, "Mucormycosis caused by unusual mycormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species", Clini Microbiol Rev, 24, pp.411~445 (2011)
- Kursun E, "Evaluation of 28 cases of mucormycosis", Mycoses, 58, pp.82~87 (2015)
- Yohai RA, "Survival factors in rhino-orbital-cerebral mycormycosis", Surv Ophthalmol, 39, pp.3~22 (1994)
- Lass-Florl, "Zygomycosis : conventional laboratory diagnosis", Clin Microbiol Infect, 5(Suppl 5), pp.60~65 (2009)
- Talmi YP, "Rhino-orbital and rhino-orbito-cerebral mucormycosis", Otolaryngol Head Neck Surg, 127, pp.22~31 (2002)
- Rapidis AD, "Orbitomaxillary mucormycosis(zygomycosis)and the surgical approach to treatment : perspectives from a maxillofacial surgeon", Clin Microbiol Infect, 15, pp.98~102 (2009)
- Mullane K, "Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections", Transpl Infect Dis, 9, pp.89~96 (2007)
- Ruping MJ, "Forty-one recent cases of invasive zygomycosis from a global clinical registry", J Antimicrob Chemother, 65, pp.296~302 (2010)
- 김우재, "털곰팡이증: Amphotericin B 치료 실패 후 Posaconazole로 호전된 1예", 대한내과학회지, 79(5), pp.587~591 (2010), 대한내과학회
- 이효진, "Posaconazole Treatment in Korea: Single-Center Experience Over 5 Years", Yonsei Medical Journal, 54(5), pp.1234~1240 (2013), 연세대학교의과대학[DOI]